{
    "relation": [
        [
            "Company",
            "ELLIE MAE I\u2026",
            "GIGOPTIX IN\u2026",
            "AMEDISYS IN\u2026",
            "COTT CORP Q\u2026",
            "BOYD GAMING\u2026"
        ],
        [
            "Symbol",
            "ELLI",
            "GIG",
            "AMED",
            "COT",
            "BYD"
        ],
        [
            "Price",
            "78.45",
            "2.34",
            "43.63",
            "11.24",
            "17.09"
        ],
        [
            "%Chg",
            "+13.48%",
            "+4.93%",
            "+2.06%",
            "+1.35%",
            "+0.83%"
        ]
    ],
    "pageTitle": "J&J Beats, 2012 Outlook Disappoints - January 24, 2012 - Zacks.com",
    "title": "",
    "url": "http://www.zacks.com/stock/news/68320/jampj-beats-2012-outlook-disappoints",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 2,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989301.17/warc/CC-MAIN-20150728002309-00270-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 840287567,
    "recordOffset": 840261014,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{65707=Copyright \u00a9 2015 Zacks Investment Research, 21385=Full year 2011 earnings came in at $5.00, 5% above the year-ago earnings of $4.76 per share and 4 cents above the Zacks Consensus Estimate. Earnings came in at the top end of the company\u2019s guidance of $4.95 - $5.00 per share. Meanwhile, revenues came in at $65 billion, up 5.6% from the year-ago period and in-line with the Zacks Consensus Estimate and the company\u2019s guidance., 24092=The Consumer segment recorded revenues of $3.7 billion in the reported quarter, up 1.6% from the fourth quarter of 2010. While operational factors increased sales in the segment by 2.7%, foreign currency movement negatively impacted sales by 1.1%. Sales in the domestic market increased 2.4% year-over-year to $1.2 billion, whereas the international market recorded a 1.2% year-over-year increase to $2.4 billion., 65768=At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm., 24835=Following the release of fourth quarter results, Johnson & Johnson provided its outlook for 2012. The company expects earnings of $5.05 to $5.15 per share, reflecting 3.5% -5.5% operational growth. Currency fluctuations are expected to have a negative impact of about 2.5%. 2012 earnings guidance is well below expectations with the Zacks Consensus Estimate currently standing at $5.22 per share., 24769=2012 Earnings Guidance Disappoints, 25300=We currently have a Neutral recommendation on Johnson and Johnson, which carries a Zacks #4 Rank (short-term Sell rating). With the company guiding below expectations for 2012, we expect the stock to be under pressure in the near-term., 14894=by Zacks Equity Research \u00a0\u00a0Published on January 24, 2012 |, 20216=Johnson & Johnson (JNJ - Analyst Report) posted fourth quarter 2011 earnings (excluding special items) of $1.13 per share, three cents above the Zacks Consensus Estimate of $1.10 and 9.7% above the year-ago earnings of $1.03., 21776=Including one-time items, Johnson & Johnson reported 2011 earnings of $3.49, down 27% from the year-ago period., 24520=The series of OTC product recalls and the suspension of manufacturing at Fort Washington facility hampered US OTC/Nutritionals sales. Fourth quarter 2011 OTC/Nutritionals sales declined 2.9% in the US mainly due to supply constraints.}",
    "lastModified": "Sun, 02 Aug 2015 17:54:36 -0500",
    "textBeforeTable": "Income Momentum Value Growth Zacks #1 Rank Top Movers for Aug 2, 2015 Zacks #1 Rank Top Movers Zacks #1 Rank Top Movers for 08/02/15 } } document.getElementById('score_val').className = ''; document.getElementById('score_val').innerHTML = ''; document.getElementById('tab_label').innerHTML = tab_text; { else } document.getElementById('score_val').className = 'scores_val'; document.getElementById('score_val').innerHTML = 'A'; document.getElementById('tab_label').innerHTML = tab_text+ ' Score'; { if(tab_text != 'income') document.getElementById('rank_text').innerHTML = cat_uri; var cat_uri = 'View All Zacks Rank #1 '+tab_text+' Stocks'; var cat_uri = '/stocks/buy-list/'+tab_text; { function footer_text(tab_text)",
    "textAfterTable": "Company Symbol Price %Chg SKYWEST INC\u2026 SKYW 16.56 +18.37% NCI INC-CL\u2026 NCIT 11.25 +11.61% MARCUS CORP\u2026 MCS 20.96 +2.69% UPM-KYMMENE\u2026 UPMKY 18.42 +1.88% SYKES ENTRP\u2026 SYKE 24.38 +1.75% Company Symbol Price %Chg ELLIE MAE I\u2026 ELLI 78.45 +13.48% GIGOPTIX IN\u2026 GIG 2.34 +4.93% AMEDISYS IN\u2026 AMED 43.63 +2.06% COTT CORP Q\u2026 COT 11.24 +1.35%",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}